2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
5
Neoplasm Metastasis
3
Stomach Neoplasms
2
Melanoma
2
Advanced Solid Tumors
2
Urinary Bladder Neoplasms
1
Unspecified Adult Solid Tumor, Protocol Specific
1
Triple Negative Breast Neoplasms
1
Solid Tumors
1
Solid Tumor
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Transitional Cell
1
Adenocarcinoma of the Stomach
1
Interventions
pembrolizumab
163
Carboplatin
146
Paclitaxel
125
Cyclophosphamide
94
130-nm albumin-bound paclitaxel
66
Capecitabine
64
Gemcitabine
54
Doxorubicin
50
Albumin-Bound Paclitaxel
45
Taxes
42
atezolizumab
41
Cisplatin
39
sacituzumab govitecan
34
Nivolumab
34
olaparib
32
Epirubicin
32
Specimen Handling
28
Docetaxel
28
eribulin
27
Bevacizumab
26
durvalumab
25
Drug Therapy
25
Biopsy
24
camrelizumab
23
Magnetic Resonance Spectroscopy
22
toripalimab
19
Radiotherapy
17
spartalizumab
16
Everolimus
15
veliparib
14
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Triple Negative Breast Neoplasms
×
tesetaxel
×
Clear all
NCT03952325
2021-07-30
CONTESSA TRIO
Odonate Therapeutics, Inc.
Phase 2
Terminated
294 enrolled